Johnson & Johnson (NYSE:JNJ) Shares Up 0.1%

Johnson & Johnson (NYSE:JNJ - Get Free Report) shares shot up 0.1% during mid-day trading on Tuesday . The stock traded as high as $167.72 and last traded at $167.15. 689,452 shares changed hands during trading, a decline of 90% from the average session volume of 7,154,924 shares. The stock had previously closed at $166.99.

Analyst Ratings Changes

Several equities analysts have weighed in on JNJ shares. TD Cowen dropped their target price on Johnson & Johnson from $195.00 to $185.00 and set a "buy" rating for the company in a research report on Thursday, July 18th. Morgan Stanley increased their target price on shares of Johnson & Johnson from $167.00 to $169.00 and gave the stock an "equal weight" rating in a report on Thursday, July 18th. StockNews.com upgraded shares of Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a research note on Saturday. Sanford C. Bernstein increased their price objective on Johnson & Johnson from $161.00 to $171.00 in a research note on Thursday, July 18th. Finally, Daiwa Capital Markets cut Johnson & Johnson from an "outperform" rating to a "neutral" rating and lowered their target price for the stock from $160.00 to $150.00 in a research note on Tuesday, July 23rd. Seven analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $173.21.

Johnson & Johnson Stock Up 0.0 %

The firm's 50-day moving average price is $160.38 and its two-hundred day moving average price is $154.01. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.85 and a current ratio of 1.07. The firm has a market cap of $402.08 billion, a PE ratio of 10.42, a P/E/G ratio of 2.71 and a beta of 0.53.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings data on Wednesday, July 17th. The company reported $2.82 earnings per share for the quarter, beating analysts' consensus estimates of $2.71 by $0.11. The company had revenue of $22.45 billion during the quarter, compared to analysts' expectations of $22.33 billion. Johnson & Johnson had a return on equity of 36.60% and a net margin of 46.34%. The firm's revenue for the quarter was up 4.3% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.80 earnings per share. As a group, equities research analysts expect that Johnson & Johnson will post 10.02 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 10th. Stockholders of record on Tuesday, August 27th were paid a dividend of $1.24 per share. The ex-dividend date of this dividend was Tuesday, August 27th. This represents a $4.96 annualized dividend and a dividend yield of 2.97%. Johnson & Johnson's dividend payout ratio (DPR) is 30.92%.

Insider Activity at Johnson & Johnson

In other Johnson & Johnson news, VP Robert J. Decker sold 5,635 shares of Johnson & Johnson stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $165.06, for a total value of $930,113.10. Following the transaction, the vice president now directly owns 18,973 shares in the company, valued at approximately $3,131,683.38. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.16% of the stock is currently owned by insiders.

Institutional Trading of Johnson & Johnson

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Norges Bank purchased a new position in Johnson & Johnson in the fourth quarter worth $4,071,642,000. Wellington Management Group LLP increased its holdings in shares of Johnson & Johnson by 16.4% in the 4th quarter. Wellington Management Group LLP now owns 24,019,725 shares of the company's stock valued at $3,764,852,000 after purchasing an additional 3,391,657 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its stake in shares of Johnson & Johnson by 16.8% in the first quarter. Price T Rowe Associates Inc. MD now owns 21,834,359 shares of the company's stock valued at $3,453,978,000 after purchasing an additional 3,139,499 shares during the period. Massachusetts Financial Services Co. MA boosted its holdings in Johnson & Johnson by 10.8% during the second quarter. Massachusetts Financial Services Co. MA now owns 18,780,645 shares of the company's stock worth $2,744,979,000 after buying an additional 1,831,751 shares in the last quarter. Finally, Ameriprise Financial Inc. grew its position in Johnson & Johnson by 5.5% during the second quarter. Ameriprise Financial Inc. now owns 14,374,397 shares of the company's stock worth $2,100,427,000 after buying an additional 754,200 shares during the period. Hedge funds and other institutional investors own 69.55% of the company's stock.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.